The Relative Strength (RS) Rating for Natera jumped into a new percentile Tuesday, as it got a lift from 63 to 71.
Can You Really Time The Stock Market?
IBD's proprietary RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the market's biggest winners often have an RS Rating of over 80 as they launch their biggest runs. See if Natera can continue to show renewed price strength and clear that threshold.
Natera is building a consolidation with a 183.00 buy point. See if the stock can clear the breakout price in volume at least 40% above average. Keep in mind that it's a later-stage consolidation, and those are riskier than earlier-stage patterns.
Natera showed 0% EPS growth in the latest quarterly report, while sales growth came in at 32%.
The company earns the No. 17 rank among its peers in the Medical-Services industry group. GeneDx Holdings, Hims & Hers Health and Precipio are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Technical Action?
